Richard A. Larson to Induction Chemotherapy
This is a "connection" page, showing publications Richard A. Larson has written about Induction Chemotherapy.
Connection Strength
0.910
-
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.
Score: 0.395
-
Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.
Score: 0.150
-
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017 Mar 30; 129(13):1763-1767.
Score: 0.132
-
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant. 2015 Mar; 21(3):559-64.
Score: 0.114
-
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.
Score: 0.039
-
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015 Mar; 29(3):567-75.
Score: 0.028
-
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
Score: 0.026
-
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60.
Score: 0.025